A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Completed · Phase 3 · NCT03734016
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $133,910
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 652
About the trial
- Sponsor
- BeiGene
- Tested
- Zanubrutinib (drug), Ibrutinib (drug)
- Dates
- Started 2018-11-01; completion 2024-02-28
- Results posted
- Yes
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
From ClinicalTrials.gov, last updated 2025-03-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $133,910 in research payments for this study in 2025 (25 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Herbert A. Eradat, M.D., M.S. Internal Medicine · Los Angeles, CA
- Don A. Stevens, M.D. Medical Oncology · Louisville, KY
- Danielle M. Brander, M.D. Hematology & Oncology · Durham, NC
- Stephen E. Spurgeon, MD Internal Medicine · Portland, OR
- Manuel A. Santiago, MD Hematology & Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ohsu Hospital and Clinics, OR $99,962
- Ronald Reagan UCLA Medical Center, CA $17,880
- Duke University , $8,417
- Texas Oncology-Amarillo Cancer Center $7,150
- Wcg Irb $500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.